WATCHconviction 3published 2026-09-10

VMD — Viemed Healthcare, Inc. · 2026-09-10 · Verdict: WATCH · Conviction 3

Price $8.76 (screen row, 2026-09-10 run; no live quote) · Mkt cap $334M · EV $330M · EV/normalised EBIT 12.9x · EV/normalised after-tax profit 17.2x · FCF yield 10.3% reported, 7.6% after stock comp · Net cash $3.3M · ADV $3.5M Sources read: 10-K 2026-03-04 (Items 1, 1A, 7), 10-Q 2026-08-03 (Item 2), DEF 14A 2026-04-22, 8-Ks 2026-05-05, 2026-06-04, 2026-08-03, Form 4s (12m), Q2 2026 call transcript (Alpha Vantage, retrieved 2026-09-05).

Desk stats

1. What the business does

Viemed rents home medical equipment and supplies the clinical labour around it, mostly for chronic respiratory disease. Ventilator rentals were 50.6% of FY2025 revenue and 46.6% of Q2 2026 revenue (10-K Item 1). Around that core sit PAP therapy and resupply, oxygen, airway clearance, a women's health line acquired with Lehan, and staffing. The differentiator is 417 licensed respiratory therapists, 29% of headcount, who set patients up at home and keep them on therapy. Medicare and Medicaid were 40% of FY2025 revenue.

2. Why it might be mispriced: the edge case

There is a candidate, and it is only half convincing. The mix shift into resupply and maternal health lowers gross margin (57.7% in Q2 2026 versus 60% in Q4 2024) and Adjusted EBITDA margin (17.6% versus 22.7%), but those lines "require substantially less capital" (Zehnder, Q2 call). Net capex ran 8.3% of revenue in the first half against a 9.0-10.5% guide, since cut to 8.5-10.0%. A screen reader sees margin compression where cash economics are flat to better. With two sell-side analysts on the call and a $334M cap, that nuance is not arbitraged quickly, and the stock is down roughly 24% from the $11.50-plus at which directors sold in late June.

The offset kills it as a clean IDEA. That $34.4M of free cash flow adds back $9.0M of stock compensation; owner earnings are nearer $25.4M, a 7.6% yield. In June 2026 shareholders raised the LTIP reserve to 7,696,717 shares, 20% of those outstanding (8-K 2026-06-04), and buybacks of 2.66M shares since 2025 still left net share count down only 1.8%.

3. Unit economics

SG&A rose to 47.5% of revenue from 45.7% on sales compensation, phantom-stock revaluation, technology spend and "temporary duplication as we bring portions of our sleep and resupply operations in-house" (Q2 call). Normalised pre-tax return on $144M of equity plus $7M of debt is about 12%, flat while revenue grew over 20%. Ventilator census hit a record 12,635, up 4.0%; PAP patients rose 44% (Q2 release). Patient growth is genuine; profit per patient is not.

4. Balance sheet and capital allocation

Clean: $10.7M cash, a $7.4M term loan maturing November 2027, $46M undrawn, $1.3M of debt service within twelve months (10-Q). Insiders sold a net 166,802 shares for $1.59M over twelve months with zero open-market purchases: President Michael Moore sold 136,802 at $8.77-$9.42 in March 2026, still holding 1.586M; a director and the CMO sold 30,000 more at $11.41-$11.72 in late June (Form 4s). Pay is equity-led: COO Zehnder took a $2.87M grant on a $478,996 salary (DEF 14A).

5. Management: said versus did

Zehnder told an analyst the business is accepting "a structurally lower EBITDA margin with no CapEx" and expects net income margins to expand as a result (Q2 call), a candid framing. The mark against them is cutting the EBITDA guide in the same release that raised revenue, leaving the year dependent on H2 margin rising from 18.3% to 22.4-24.0%. That is roughly last year's H2 margin of 23.2%, so not fantasy, but unproven, and it is the whole thesis.

6. Valuation

Reverse DCF: at EV $330M against $19.2M of normalised after-tax operating profit and a 10% cost of capital, the current price implies about 4.2% perpetual growth in after-tax operating profit, a low bar against 20%+ revenue growth but one the company has cleared at 0% over the past twelve months. Cases below take FY2027 revenue at an Adjusted EBITDA margin, less $10M stock comp and $34M D&A, taxed at 28%.

Probability-weighted: about $9.03 against $8.76. Wide, but not skewed enough to pay for.

7. Catalysts and timeline

Q3 2026 results in early November, the first clean read on the H2 margin recovery. Continued 2026 buyback (1,930,131 authorised, 680,802 done at 30 June). The February 2026 six-month DMEPOS enrolment moratorium may be extended, slowing acquisitions (10-K Item 1A).

8. Risks and pre-registered kill criteria

Principal risks: 40% of revenue from Medicare and Medicaid under a coverage determination only fifteen months old; post-payment audit and recoupment exposure inherent to DME billing (10-K Item 1A); dilution at a 20% plan reserve.

  1. FY2026 Adjusted EBITDA below $64M, the low end of the 2026-08-03 guide, or H2 2026 Adjusted EBITDA margin below 21%.
  2. Ventilator census declines sequentially for two consecutive quarters from 12,635.
  3. Net capex back above 10.0% of revenue for two consecutive quarters while gross margin stays below 58%.
  4. TTM free cash flow less stock compensation falls below $20M, from $25.4M at 30 June 2026.

9. Verdict and summary

WATCH, conviction 3. Viemed is a real, clean, growing business: record patient counts, net cash, a 10% headline free cash flow yield and candid management. But the screen picked it up on FY2025 operating profit growth of 28%, and that number is stale. On a trailing twelve-month basis operating profit is flat at $22.8M despite revenue up more than 20%, Q2 Adjusted EBITDA fell 4% year over year, and the company cut EBITDA guidance in the same release that raised revenue guidance. The real insight is that the shift into resupply and maternal health depresses EBITDA margin while cutting capital intensity, so cash economics beat the margin line. Against that, roughly a third of the headline free cash flow is stock compensation, paid under a plan reserve equal to 20% of the company, and insiders sold $1.6M with no open-market buying. At $8.76 the price already implies about 4% perpetual growth in after-tax operating profit, and a probability-weighted $9 leaves no margin of safety. The 2026 guide rests entirely on second-half margin recovering from 18.3% to roughly 23%, which the Q3 print in November will test. Watch it, do not buy it here.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.

Source markdown: 2026-09-10_VMD.md · how these notes are built · every verdict tracked since publication.

Research and education only. Nothing here is investment advice or a recommendation to buy or sell any security. No price targets are recommendations; positions and sizing are the reader's decision. Past performance does not predict future results.